Special lssues
Table of Content

Intestinal Epithelial Cells in Health and Disease

Submission Deadline: 31 May 2024 Submit to Special Issue

Guest Editors

Dr. Weiqi He, Cambridge-Su Genomic Resource Center, Suzhou Medical College of Soochow University, China.

Dr. Le Shen, Molecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, USA


The inner lining of the intestine is composed of a singular layer of epithelial cells. Sustained renewal of these cells is orchestrated by the continual proliferation of stem cells located at the crypt's base. These epithelial cells collectively form a vital barrier, safeguarding the internal environment of the body against external agents and preventing the onset of inflammation. Crucially, the persistence of epithelial cells and the proper functioning of the mucosal barrier lie at the heart of the pathogenesis of intestinal disorders, including inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CA-CRC).


In this special edition, we extend a warm invitation for the submission of manuscripts that delve into the intricacies of intestinal stem cell biology, epithelial regeneration, and the functional aspects of the epithelial barrier in both healthy and diseased states.


We encourage contributions covering a broad spectrum of topics, including but not limited to:

• Intestinal stem cells

• Intestinal organoids

• Epithelial barrier function

• Epithelial cell death

• Mucosal immunology

• Inflammatory bowel disease

• Colitis-associated colorectal cancer

• Colorectal cancer

• Gut microbiota

• Circadian clock and gut homeostasis


Authors are invited to explore these areas and contribute valuable insights to further our understanding of intestinal health and disease.


intestinal stem cell, barrier function, inflammatory bowel disease, colitis, colorectal cancer, circadian clock, organoids

Published Papers

  • Open Access


    OPA3 overexpression modulates lipid droplet production and sensitizes colorectal cancer cells to bevacizumab treatment

    BIOCELL, DOI:10.32604/biocell.2024.049466
    (This article belongs to the Special Issue: Intestinal Epithelial Cells in Health and Disease)
    Abstract Background: Colorectal cancer (CRC) represents a substantial risk to public health. Bevacizumab, the first US FDA-approved antiangiogenic drug (AAD) for human CRC treatment, faces resistance in patients. The role of lipid metabolism, particularly through OPA3-regulated lipid droplet production, in overcoming this resistance is under investigation. Methods: The protein expression pattern of OPA3 in CRC primary/normal tissues was evaluated by bioinformatics analysis. OPA3-overexpressed SW-480 and HCT-116 cell lines were established, and bevacizumab resistance and OPA3 effects on cell malignancy were examined. OPA3 protein/mRNA expression and lipid droplet-related genes were measured with Western blot and qRT-PCR. OPA3… More >

    Graphic Abstract

    OPA3 overexpression modulates lipid droplet production and sensitizes colorectal cancer cells to bevacizumab treatment

Share Link